Grandis, M.
Obici, L.
Luigetti, M.
Briani, C.
Benedicenti, F.
Bisogni, G.
Canepa, M.
Cappelli, F.
Danesino, C.
Fabrizi, G. M.
Fenu, S.
Ferrandes, G.
Gemelli, C.
Manganelli, F.
Mazzeo, A.
Melchiorri, L.
Perfetto, F.
Pradotto, L. G.
Rimessi, P.
Tini, G.
Tozza, S.
Trevisan, L.
Pareyson, D.
Mandich, P. http://orcid.org/0000-0003-3123-3512
Funding for this research was provided by:
Independent Health Educational Grant from Pfizer
Article History
Received: 4 May 2020
Accepted: 27 November 2020
First Online: 14 December 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The authors declare that they have no competing interests.
: M. Grandis acknowledges donations from Sanofi Genzyme to support research activities of her Research Unit; financial support from Alnylam and Sanofi Genzyme for participation in National and International Meetings; speaker honorarium from Sanofi Genzyme. L. Obici acknowledges speaker and consultation honoraria from Akcea, Alnylam and Pfizer. M. Luigetti received financial grants (honoraria and speaking) from Akcea, Alnylam and Pfizer, and travel grants from Akcea, Alnylam, Pfizer, Kedrion, CSL Behring and Grifols. C. Briani reports speaker and consulting honoraria from Akcea, Alnylam and Pfizer, and travel grants from Kedrion, Alnylam and CSL Behring. G. Bisogni reports financial grants (honoraria and speaking) from Alnylam, travel grants from Alnylam, Pfizer and Grifols. M. Canepa received speaker and advisor fees from Akcea Therapeutics, Menarini, Novartis, Pfizer, Sanofi and Sanofi Genzyme, Vifor Pharma, and an investigator-initiated grant from Pfizer. G. M. Fabrizi was sponsored by Akcea Therapeutics to attend the 2019 American Academy of Neurology Conference in Philadelphia and by Pfizer Inc. to attend the 2018 ARia (Advances and Research in TTR Amyloidosis) VII symposium, in Frankfurt. GMF received fees for Board membership from Akcea Therapeutics (Akcea Scientific Advisory Board, Milan January 29 2019) and Alnylam Pharmaceuticals (Alnylam Scientific Advisory Board, Milan December 11 2019). S. Fenu acknowledges financial support from Alnylam, Akcea and Pfizer for participation in National and International Meetings; participation in Advisory Board of Akcea. C. Gemelli reports grants to attend scientific meetings from Sanofi Genzyme and Pfizer. F. Manganelli received personal fees for scientific events from Alfa-Sigma, Alnylam and Akcea and has received travel grant to attend scientific meeting from CSL Behring. A. Mazzeo reports participation in Advisory Board of Pfizer, Alnylam, Akcea. F. Perfetto received speaker honoraria from Pfizer, Alnylam Pharmaceuticals and Akcea. L.G. Pradotto received financial grants (honoraria and speaking) from Akcea and Alnylam, and travel grants from Akcea, Alnylam, and Pfizer. D. Pareyson acknowledges donations from Pfizer, LAM Therapeutics and Acceleron to support research activities of his Research Unit; financial support from Pfizer, Alnylam and Kedrion for participation in National and International Meetings; participation in Advisory Board of Inflectis, Alnylam and Akcea; speaker honorarium from Alnylam. P. Mandich was sponsored by Independent Health Educational Grant from Pfizer (2018). F. Benedicenti, F. Cappelli, C. Danesino, G. Ferrandes, L. Melchiorri, P. Rimessi, G. Tini, S. Tozza, L. Trevisan have no disclosures.